Tianqing Gan Mei and Meineng are both glycyrrhizic acid preparations, Meineng is the third generation glycyrrhizic acid preparation, and Gan Mei is the latest generation glycyrrhizic acid preparation. In recent years, it is the only first-class new drug in the field of liver diseases, and has won many patents and national invention gold awards. Because of its unique chiral chemical structure, it is easier to combine with receptor protein than Meineng, so it has higher liver distribution targeting, which is more than twice that of Meineng. It has good anti-inflammatory and liver-protecting effects. The high distribution of liver determines that other organs and tissues are less distributed. Compared with Meineng, its distribution in kidney is one quarter of that of Meineng, so Gan Mei has low nephrotoxicity while resisting inflammation and protecting liver. In the second and third clinical studies, no side effects of pseudoaldosterone syndrome were found.
Just ask a doctor in the field of liver disease above grade A, and you will know which is better, sweet or beautiful!